TargetMol

Tadalafil

Product Code:
 
TAR-T1398
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1398-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1398-25mg25mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1398-50mg50mg£129.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1398-100mg100mg£160.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1398-200mg200mg£232.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tadalafil is a carboline-based compound with vasodilatory activity. Tadalafil selectively inhibits the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase- (PDE-5)-mediated degradation of cGMP, which is found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis. Inhibition of cGMP degradation by tadalafil results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection.
CAS:
171596-29-5
Formula:
C22H19N3O4
Molecular Weight:
389.4
Pathway:
Metabolism; Apoptosis
Purity:
0.9953
SMILES:
C1N(C(=O)[C@@H]2N(C1=O)[C@@H](c1c(C2)c2c([nH]1)cccc2)c1ccc2c(c1)OCO2)C
Target:
Apoptosis; PDE

References

1. Blount MA, et al. Mol Pharmacol, 2004, 66(1), 144-152. 2. Ring BJ, et al. Clin Pharmacol Ther, 2005, 77(1), 63-75. 3. Vignozzi L, et al. J Sex Med, 2006, 3(3), 419-431. 4. Zhang L, et al. Brain Res, 2006, 1118(1), 192-198. 5. Lysiak JJ, et al. J Urol, 2008, 179(2), 779-785.